Ferring Pharmaceuticals: Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection (DDW)
RBX2660 is the first microbiota-based live biotherapeutic to demonstrate efficacy as early as first recurrence of Clostridioides difficile (C. difficile) infection
RBX2660 Phase 3 data add to the world s largest and most robust clinical program ever conducted in the field of microbiome-based therapeutics
Findings build on previous RBX2660 clinical trials showing repeated efficacy and consistent safety, including two trials with two years of safety follow-up
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today presented results from the pivotal Phase 3 PUNCH CD3 clinical trial, demonstrating superior efficacy and consistent safety of single-dose RBX2660 in reducing recurrence of